Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol

Carl B. Camras, Martin B. Wax, Robert Ritch, Robert Weinreb, Alan L. Robin, Eve J. Higginbotham, Jacqueline Lustgarten, William C. Stewart, Mark Sherwood, Theodore Krupin, Jacob Wilensky, George A. Cioffi, L. Jay Katz, Robert A. Schumer, Paul L. Kaufman, Don Minckler, Thom Zimmerman, Johan Stjernschantz

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

PURPOSE: To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy. METHODS: Latanoprost 0.005% was topically applied once daily without masking for 6 months in 223 patients with elevated intraocular pressure after previous treatment with latanoprost once daily or 0.5% timolol twice daily for 6 months in a multicenter, randomized, double-masked, parallel group study. RESULTS: Compared with baseline values before treatment, a significant (P < .0001) diurnal reduction in intraocular pressure of 6 to 8 mm Hg was maintained with minimal fluctuation for the duration of treatment. When treatment was switched from timolol to latanoprost, intraocular pressure was reduced by 1.5 ± 0.3 mm Hg (mean ± SEM; 8% change in intraocular pressure; 31% of the intraocular pressure reduction produced by timolol; P < .001) compared with the change in intraocular pressure in patients remaining on latanoprost therapy. Of the patients initially enrolled, 95% successfully completed treatment. There was a slight overall increase in conjunctival hyperemia in patients who switched from timolol to latanoprost, but no change in those who continued latanoprost. The timolol-induced reduction of resting heart rate returned to baseline levels after switching to latanoprost. Of the 247 patients treated with latanoprost during the masked and/or open-label studies, 12 (5%) demonstrated a definite (n = 4) or possible (n = 8) increase in iris pigmentation. CONCLUSIONS: Latanoprost is a well-tolerated ocular hypotensive agent that appears to be more effective than timolol in reducing intraocular pressure. The increase in iris pigmentation appears to be harmless but requires further investigation.

Original languageEnglish (US)
Pages (from-to)390-399
Number of pages10
JournalAmerican Journal of Ophthalmology
Volume126
Issue number3
DOIs
StatePublished - Sep 1998

Fingerprint

latanoprost
Timolol
Glaucoma
Intraocular Pressure
Therapeutics
Pigmentation
Iris

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Camras, C. B., Wax, M. B., Ritch, R., Weinreb, R., Robin, A. L., Higginbotham, E. J., ... Stjernschantz, J. (1998). Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. American Journal of Ophthalmology, 126(3), 390-399. https://doi.org/10.1016/S0002-9394(98)00094-4

Latanoprost treatment for glaucoma : Effects of treating for 1 year and of switching from timolol. / Camras, Carl B.; Wax, Martin B.; Ritch, Robert; Weinreb, Robert; Robin, Alan L.; Higginbotham, Eve J.; Lustgarten, Jacqueline; Stewart, William C.; Sherwood, Mark; Krupin, Theodore; Wilensky, Jacob; Cioffi, George A.; Katz, L. Jay; Schumer, Robert A.; Kaufman, Paul L.; Minckler, Don; Zimmerman, Thom; Stjernschantz, Johan.

In: American Journal of Ophthalmology, Vol. 126, No. 3, 09.1998, p. 390-399.

Research output: Contribution to journalArticle

Camras, CB, Wax, MB, Ritch, R, Weinreb, R, Robin, AL, Higginbotham, EJ, Lustgarten, J, Stewart, WC, Sherwood, M, Krupin, T, Wilensky, J, Cioffi, GA, Katz, LJ, Schumer, RA, Kaufman, PL, Minckler, D, Zimmerman, T & Stjernschantz, J 1998, 'Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol', American Journal of Ophthalmology, vol. 126, no. 3, pp. 390-399. https://doi.org/10.1016/S0002-9394(98)00094-4
Camras, Carl B. ; Wax, Martin B. ; Ritch, Robert ; Weinreb, Robert ; Robin, Alan L. ; Higginbotham, Eve J. ; Lustgarten, Jacqueline ; Stewart, William C. ; Sherwood, Mark ; Krupin, Theodore ; Wilensky, Jacob ; Cioffi, George A. ; Katz, L. Jay ; Schumer, Robert A. ; Kaufman, Paul L. ; Minckler, Don ; Zimmerman, Thom ; Stjernschantz, Johan. / Latanoprost treatment for glaucoma : Effects of treating for 1 year and of switching from timolol. In: American Journal of Ophthalmology. 1998 ; Vol. 126, No. 3. pp. 390-399.
@article{efcad664ab074cb598e34cc0afdf0bdc,
title = "Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol",
abstract = "PURPOSE: To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy. METHODS: Latanoprost 0.005{\%} was topically applied once daily without masking for 6 months in 223 patients with elevated intraocular pressure after previous treatment with latanoprost once daily or 0.5{\%} timolol twice daily for 6 months in a multicenter, randomized, double-masked, parallel group study. RESULTS: Compared with baseline values before treatment, a significant (P < .0001) diurnal reduction in intraocular pressure of 6 to 8 mm Hg was maintained with minimal fluctuation for the duration of treatment. When treatment was switched from timolol to latanoprost, intraocular pressure was reduced by 1.5 ± 0.3 mm Hg (mean ± SEM; 8{\%} change in intraocular pressure; 31{\%} of the intraocular pressure reduction produced by timolol; P < .001) compared with the change in intraocular pressure in patients remaining on latanoprost therapy. Of the patients initially enrolled, 95{\%} successfully completed treatment. There was a slight overall increase in conjunctival hyperemia in patients who switched from timolol to latanoprost, but no change in those who continued latanoprost. The timolol-induced reduction of resting heart rate returned to baseline levels after switching to latanoprost. Of the 247 patients treated with latanoprost during the masked and/or open-label studies, 12 (5{\%}) demonstrated a definite (n = 4) or possible (n = 8) increase in iris pigmentation. CONCLUSIONS: Latanoprost is a well-tolerated ocular hypotensive agent that appears to be more effective than timolol in reducing intraocular pressure. The increase in iris pigmentation appears to be harmless but requires further investigation.",
author = "Camras, {Carl B.} and Wax, {Martin B.} and Robert Ritch and Robert Weinreb and Robin, {Alan L.} and Higginbotham, {Eve J.} and Jacqueline Lustgarten and Stewart, {William C.} and Mark Sherwood and Theodore Krupin and Jacob Wilensky and Cioffi, {George A.} and Katz, {L. Jay} and Schumer, {Robert A.} and Kaufman, {Paul L.} and Don Minckler and Thom Zimmerman and Johan Stjernschantz",
year = "1998",
month = "9",
doi = "10.1016/S0002-9394(98)00094-4",
language = "English (US)",
volume = "126",
pages = "390--399",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Latanoprost treatment for glaucoma

T2 - Effects of treating for 1 year and of switching from timolol

AU - Camras, Carl B.

AU - Wax, Martin B.

AU - Ritch, Robert

AU - Weinreb, Robert

AU - Robin, Alan L.

AU - Higginbotham, Eve J.

AU - Lustgarten, Jacqueline

AU - Stewart, William C.

AU - Sherwood, Mark

AU - Krupin, Theodore

AU - Wilensky, Jacob

AU - Cioffi, George A.

AU - Katz, L. Jay

AU - Schumer, Robert A.

AU - Kaufman, Paul L.

AU - Minckler, Don

AU - Zimmerman, Thom

AU - Stjernschantz, Johan

PY - 1998/9

Y1 - 1998/9

N2 - PURPOSE: To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy. METHODS: Latanoprost 0.005% was topically applied once daily without masking for 6 months in 223 patients with elevated intraocular pressure after previous treatment with latanoprost once daily or 0.5% timolol twice daily for 6 months in a multicenter, randomized, double-masked, parallel group study. RESULTS: Compared with baseline values before treatment, a significant (P < .0001) diurnal reduction in intraocular pressure of 6 to 8 mm Hg was maintained with minimal fluctuation for the duration of treatment. When treatment was switched from timolol to latanoprost, intraocular pressure was reduced by 1.5 ± 0.3 mm Hg (mean ± SEM; 8% change in intraocular pressure; 31% of the intraocular pressure reduction produced by timolol; P < .001) compared with the change in intraocular pressure in patients remaining on latanoprost therapy. Of the patients initially enrolled, 95% successfully completed treatment. There was a slight overall increase in conjunctival hyperemia in patients who switched from timolol to latanoprost, but no change in those who continued latanoprost. The timolol-induced reduction of resting heart rate returned to baseline levels after switching to latanoprost. Of the 247 patients treated with latanoprost during the masked and/or open-label studies, 12 (5%) demonstrated a definite (n = 4) or possible (n = 8) increase in iris pigmentation. CONCLUSIONS: Latanoprost is a well-tolerated ocular hypotensive agent that appears to be more effective than timolol in reducing intraocular pressure. The increase in iris pigmentation appears to be harmless but requires further investigation.

AB - PURPOSE: To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy. METHODS: Latanoprost 0.005% was topically applied once daily without masking for 6 months in 223 patients with elevated intraocular pressure after previous treatment with latanoprost once daily or 0.5% timolol twice daily for 6 months in a multicenter, randomized, double-masked, parallel group study. RESULTS: Compared with baseline values before treatment, a significant (P < .0001) diurnal reduction in intraocular pressure of 6 to 8 mm Hg was maintained with minimal fluctuation for the duration of treatment. When treatment was switched from timolol to latanoprost, intraocular pressure was reduced by 1.5 ± 0.3 mm Hg (mean ± SEM; 8% change in intraocular pressure; 31% of the intraocular pressure reduction produced by timolol; P < .001) compared with the change in intraocular pressure in patients remaining on latanoprost therapy. Of the patients initially enrolled, 95% successfully completed treatment. There was a slight overall increase in conjunctival hyperemia in patients who switched from timolol to latanoprost, but no change in those who continued latanoprost. The timolol-induced reduction of resting heart rate returned to baseline levels after switching to latanoprost. Of the 247 patients treated with latanoprost during the masked and/or open-label studies, 12 (5%) demonstrated a definite (n = 4) or possible (n = 8) increase in iris pigmentation. CONCLUSIONS: Latanoprost is a well-tolerated ocular hypotensive agent that appears to be more effective than timolol in reducing intraocular pressure. The increase in iris pigmentation appears to be harmless but requires further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0032169880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032169880&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(98)00094-4

DO - 10.1016/S0002-9394(98)00094-4

M3 - Article

C2 - 9744372

AN - SCOPUS:0032169880

VL - 126

SP - 390

EP - 399

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -